Citadel Advisors’s BioTelemetry, Inc. BEAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-34,200
Closed -$2.46M 14108
2020
Q4
$2.46M Buy
34,200
+26,400
+338% +$1.38M ﹤0.01% 4921
2020
Q3
$356K Buy
+7,800
New +$326K ﹤0.01% 7858
2020
Q2
Sell
-18,900
Closed -$728K 10964
2020
Q1
$728K Buy
18,900
+8,800
+87% +$405K ﹤0.01% 5868
2019
Q4
$468K Sell
10,100
-200
-2% -$8.66K ﹤0.01% 6927
2019
Q3
$420K Sell
10,300
-15,100
-59% -$652K ﹤0.01% 7050
2019
Q2
$1.22M Sell
25,400
-43,000
-63% -$2.26M ﹤0.01% 5373
2019
Q1
$4.28M Buy
68,400
+26,500
+63% +$1.82M ﹤0.01% 3224
2018
Q4
$2.5M Sell
41,900
-6,600
-14% -$396K ﹤0.01% 3803
2018
Q3
$3.13M Buy
48,500
+33,200
+217% +$1.85M ﹤0.01% 3666
2018
Q2
$689K Sell
15,300
-2,500
-14% -$99.7K ﹤0.01% 5852
2018
Q1
$553K Buy
17,800
+1,400
+9% +$46K ﹤0.01% 5726
2017
Q4
$490K Sell
16,400
-2,000
-11% -$57.9K ﹤0.01% 5685
2017
Q3
$607K Buy
18,400
+8,200
+80% +$284K ﹤0.01% 5033
2017
Q2
$341K Sell
10,200
-31,400
-75% -$937K ﹤0.01% 5706
2017
Q1
$1.2M Buy
41,600
+30,000
+259% +$743K ﹤0.01% 3746
2016
Q4
$259K Sell
11,600
-6,000
-34% -$117K ﹤0.01% 5885
2016
Q3
$327K Sell
17,600
-14,800
-46% -$279K ﹤0.01% 5533
2016
Q2
$528K Buy
+32,400
New +$477K ﹤0.01% 4405
2016
Q1
Sell
-6,600
Closed -$77K 9190
2015
Q4
$77K Sell
6,600
-15,800
-71% -$200K ﹤0.01% 6951
2015
Q3
$274K Buy
22,400
+13,200
+143% +$168K ﹤0.01% 5708
2015
Q2
$87K Sell
9,200
-300
-3% -$2.78K ﹤0.01% 7227
2015
Q1
$84K Buy
9,500
+6,400
+206% +$64.7K ﹤0.01% 6991
2014
Q4
$31K Sell
3,100
-2,100
-40% -$18K ﹤0.01% 7544
2014
Q3
$35K Buy
5,200
+500
+11% +$3.51K ﹤0.01% 7129
2014
Q2
$34K Sell
4,700
-2,900
-38% -$23.1K ﹤0.01% 7022
2014
Q1
$77K Sell
7,600
-9,500
-56% -$87.4K ﹤0.01% 6417
2013
Q4
$136K Sell
17,100
-16,400
-49% -$153K ﹤0.01% 5367
2013
Q3
$332K Buy
33,500
+11,800
+54% +$92.9K ﹤0.01% 4242
2013
Q2
$128K Buy
+21,700
New +$73K ﹤0.01% 5037

Other funds holding BEAT

Citadel Advisors's BEAT Position: Q1 2021 in Review

Citadel Advisors sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 25,255 shares — an estimated $1.82M sold.

Citadel Advisors first reported a position in BEAT in Q2 2013 and held it in 29 quarters. The position peaked at $6.07M in Q2 2019. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • Citadel Advisors reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • Citadel Advisors sold 25,255 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.82M.
  • Citadel Advisors first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 29 quarters.
  • Citadel Advisors's BioTelemetry, Inc. position peaked at $6.07M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.